SG11201908531WA - Combination therapies for the treatment of breast cancer - Google Patents
Combination therapies for the treatment of breast cancerInfo
- Publication number
- SG11201908531WA SG11201908531WA SG11201908531WA SG11201908531WA SG 11201908531W A SG11201908531W A SG 11201908531WA SG 11201908531W A SG11201908531W A SG 11201908531WA SG 11201908531W A SG11201908531W A SG 11201908531WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- rule
- pct
- applicant
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 235000013418 Myrtus communis Nutrition 0.000 abstract 1
- 240000005125 Myrtus communis Species 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472345P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022961 WO2018170447A1 (fr) | 2017-03-16 | 2018-03-16 | Polythérapies pour le traitement du cancer du sein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908531WA true SG11201908531WA (en) | 2019-10-30 |
Family
ID=61874039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908531W SG11201908531WA (en) | 2017-03-16 | 2018-03-16 | Combination therapies for the treatment of breast cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11083722B2 (fr) |
| EP (2) | EP3595725B1 (fr) |
| JP (1) | JP7219224B2 (fr) |
| KR (1) | KR102517650B1 (fr) |
| CN (1) | CN110636862A (fr) |
| AU (1) | AU2018234903B2 (fr) |
| BR (1) | BR112019019261A2 (fr) |
| CA (1) | CA3056701A1 (fr) |
| IL (1) | IL269357B1 (fr) |
| MA (1) | MA47776A (fr) |
| MX (1) | MX2019010981A (fr) |
| RU (1) | RU2764724C2 (fr) |
| SG (1) | SG11201908531WA (fr) |
| WO (1) | WO2018170447A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790141B (zh) * | 2016-11-28 | 2021-06-11 | 卫材 R&D 管理有限公司 | 吲唑衍生物的盐及其晶体 |
| JP2021509680A (ja) | 2018-01-08 | 2021-04-01 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｇ１ｔ３８の優れた投与レジメン |
| KR20230104158A (ko) * | 2020-11-06 | 2023-07-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 유방암의 치료 방법 |
| CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
| WO2024115680A1 (fr) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Sels de ribociclib et formulations de ceux-ci |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| MXPA02007005A (es) | 2000-01-18 | 2004-09-06 | Aventis Pharma Inc | Pseudopolimorfo de (-) -cis-2 -(2-clorofenil) -5, 7-dihidorxi -8[4r-(3s-hidroxi -1-meitl) piperidinil] -4h-1-benzopiran -4-ona. |
| WO2001053294A1 (fr) | 2000-01-18 | 2001-07-26 | Aventis Pharmaceuticals Inc. | Solvate d'ethanol sous forme (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| US20050004007A1 (en) | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
| CA2532965C (fr) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3) |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| WO2008007113A2 (fr) | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
| US20090036435A1 (en) | 2005-01-21 | 2009-02-05 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| AU2006207321B2 (en) | 2005-01-21 | 2012-09-06 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2006077425A1 (fr) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinaisons d'inhibiteurs de pyrazole kinase et d'autres agents antitumoraux |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| US7776832B2 (en) * | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP2009543770A (ja) | 2006-07-14 | 2009-12-10 | アステックス・セラピューティクス・リミテッド | Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤 |
| US20090318430A1 (en) | 2006-07-21 | 2009-12-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| CA2734802C (fr) | 2008-08-22 | 2016-05-31 | Novartis Ag | Composes de pyrrolopyrimidine et leurs utilisations |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| AU2011240735B2 (en) | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| KR101929593B1 (ko) | 2010-10-25 | 2018-12-14 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| ES2620521T3 (es) | 2011-03-23 | 2017-06-28 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
| US9408847B2 (en) * | 2012-11-28 | 2016-08-09 | Novartis Ag | Combination therapy |
| ME03557B (fr) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Protection transitoire de cellules normales pendant une chimiothérapie |
| PL3033086T3 (pl) * | 2013-08-14 | 2022-01-31 | Novartis Ag | Terapia skojarzona do leczenia nowotworów złośliwych |
| KR20160124909A (ko) | 2014-03-13 | 2016-10-28 | 에프. 호프만-라 로슈 아게 | 에스트로겐 수용체 조절제를 함유하는 치료 조합물 |
| WO2016025650A1 (fr) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinaisons d'un inhibiteur de erk et d'un inhibiteur cdk4/6 et méthodes associées |
| WO2016040848A1 (fr) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6 |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| IL310069A (en) * | 2015-04-29 | 2024-03-01 | Radius Pharmaceuticals Inc | Cancer treatment methods |
| PE20181083A1 (es) * | 2015-05-29 | 2018-07-05 | Eisai Randd Man Co Ltd | Compuestos alqueno tetrasustituidos y su uso |
-
2018
- 2018-03-16 IL IL269357A patent/IL269357B1/en unknown
- 2018-03-16 KR KR1020197029851A patent/KR102517650B1/ko active IP Right Grant
- 2018-03-16 RU RU2019132893A patent/RU2764724C2/ru active
- 2018-03-16 JP JP2019550800A patent/JP7219224B2/ja active Active
- 2018-03-16 MA MA047776A patent/MA47776A/fr unknown
- 2018-03-16 BR BR112019019261-1A patent/BR112019019261A2/pt unknown
- 2018-03-16 CA CA3056701A patent/CA3056701A1/fr active Pending
- 2018-03-16 EP EP18715441.4A patent/EP3595725B1/fr active Active
- 2018-03-16 SG SG11201908531W patent/SG11201908531WA/en unknown
- 2018-03-16 EP EP23159590.1A patent/EP4218820A3/fr active Pending
- 2018-03-16 MX MX2019010981A patent/MX2019010981A/es unknown
- 2018-03-16 CN CN201880030008.9A patent/CN110636862A/zh active Pending
- 2018-03-16 WO PCT/US2018/022961 patent/WO2018170447A1/fr unknown
- 2018-03-16 AU AU2018234903A patent/AU2018234903B2/en active Active
- 2018-03-16 US US16/493,931 patent/US11083722B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018170447A1 (fr) | 2018-09-20 |
| US20210113537A1 (en) | 2021-04-22 |
| EP3595725B1 (fr) | 2023-05-03 |
| RU2019132893A3 (fr) | 2021-06-24 |
| AU2018234903B2 (en) | 2024-02-08 |
| KR102517650B1 (ko) | 2023-04-05 |
| JP7219224B2 (ja) | 2023-02-07 |
| RU2764724C2 (ru) | 2022-01-19 |
| MX2019010981A (es) | 2020-09-07 |
| IL269357B1 (en) | 2024-06-01 |
| EP4218820A3 (fr) | 2023-09-20 |
| RU2019132893A (ru) | 2021-04-16 |
| US11083722B2 (en) | 2021-08-10 |
| EP3595725A1 (fr) | 2020-01-22 |
| IL269357A (en) | 2019-11-28 |
| AU2018234903A1 (en) | 2019-10-10 |
| BR112019019261A2 (pt) | 2020-06-16 |
| KR20190125448A (ko) | 2019-11-06 |
| EP4218820A2 (fr) | 2023-08-02 |
| MA47776A (fr) | 2020-01-22 |
| JP2020510075A (ja) | 2020-04-02 |
| CN110636862A (zh) | 2019-12-31 |
| CA3056701A1 (fr) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908531WA (en) | Combination therapies for the treatment of breast cancer | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201811457QA (en) | Methods and devices for valve clip excision | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201910198UA (en) | Multibiotic agents and methods of using the same | |
| SG11201808231VA (en) | Delivery system | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901505SA (en) | I domain chimeric antigen receptor specific to icam-1 | |
| SG11201909513QA (en) | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy | |
| SG11201903786UA (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase |